Clinical trial
Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had…
NCT00008554 · Glaxo Wellcome, Industry · Unknown status
Key facts
| NCT number | NCT00008554 |
|---|---|
| Title | Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy |
| Official title | A Phase III, Randomised, Multicenter, Parallel, Open-Label Study to Compare the Efficacy, Safety, and Tolerability of GW433908 (1400 Mg Bid) and Nelfinavir (1250 Mg Bid) Over 48 Weeks in Antiretroviral Therapy Naive HIV-1 Infected Adults |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908 |
| Enrollment | 210 |
| Start date | Nov 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: